Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Tecfidera (dimethyl fumarate) on gut microbiota and GI adverse events in RRMS
2015-001197-18Phase 4Completed
- Sponsor
- Biogen
- Start
- Apr 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of dimethyl fumarate in multiple sclerosis (MS), sponsored by Biogen. Primary endpoint: Change in gut microbiota composition pre- vs post-dimethyl fumarate. Started Apr 2015; status: completed.
02
Drugs
dimethyl fumarate
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2015-001197-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001197-18.